# A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

> **NCT03209973** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 70 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT03209973
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-21
- **Primary completion:** 2020-11-02
- **Final completion:** 2020-11-02
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03209973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03209973, "A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03209973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*